For the quarter ending 2026-03-31, RKDA had $695K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Credit loss | - | 0 | 256 | 4,489 |
| Net income (loss) | -4,385 | -1,336 | 856 | -1,859 |
| Gain on disposal of property and equipment | - | 0 | 0 | 0 |
| Change in fair value of common stock warrant and option liabilities | 1,191 | 509 | 561 | 1,314 |
| Change in fair value of contingent consideration | 0 | 0 | 0 | -2,000 |
| Write-down of inventories | - | 0 | 0 | - |
| Issuance and offering costs | 421 | - | - | - |
| Impairment of property and equipment | - | 0 | 0 | 0 |
| Loss on january 2026 inducement offer | -2,877 | - | - | - |
| Depreciation | 8 | 2 | 2 | 28 |
| Lease amortization | 0 | 0 | 5 | 117 |
| Gain on receipt of above food ingredients, inc. common stock | - | - | - | 1,067 |
| Amortization of note receivable | 0 | 0 | 0 | -69 |
| Gain on sale of intangible assets | 0 | 0 | 0 | 750 |
| Gain on receipt of above food ingredients, inc. common stock | - | 0 | 1,067 | - |
| Unrealized loss subsequent to receipt of above food ingredients, inc. common stock | -1,538 | -461 | 1,698 | - |
| Amounts due to related parties | - | 0 | 0 | -30 |
| Write-down of non-controlling interest | - | 0 | - | - |
| Stock-based compensation | 15 | 17 | 53 | 164 |
| Accounts receivable and other receivables | 0 | -406 | -176 | 417 |
| Inventories | -372 | -244 | -33 | 585 |
| Prepaid expenses and other current assets | 28 | -58 | -173 | -544 |
| Other noncurrent assets | - | -6 | 0 | 56 |
| Accounts payable and accrued expenses | -719 | -227 | 458 | -630 |
| Other current liabilities | -7 | 0 | 0 | -57 |
| Operating lease payments | - | -122 | - | - |
| Operating lease liabilities | 139 | - | -10 | -129 |
| Net cash used in operating activities | -1,099 | -861 | -257 | -3,621 |
| Proceeds from sale of property and equipment | - | 0 | 0 | 0 |
| Proceeds from sale of investments | - | 0 | 0 | 0 |
| Proceeds from sale of rs durum wheat trait | - | - | 0 | 0 |
| Proceeds from sale of intangible assets | 0 | 0 | 0 | 750 |
| Cash paid related to sale of goodwheat | - | 0 | 0 | 0 |
| Purchases of property and equipment | - | 0 | 0 | 0 |
| Net cash provided by investing activities | 0 | 0 | 0 | 750 |
| Proceeds from january 2026 inducement offer | 2,082 | - | - | - |
| Payments of offering costs relating to january 2026 inducement offer | 288 | - | - | - |
| Proceeds from espp purchases | 0 | 0 | 1 | 5 |
| Net cash provided by financing activities | 1,794 | 0 | 1 | 5 |
| Net increase (decrease) in cash and cash equivalents | 695 | -861 | -256 | -2,866 |
| Cash and cash equivalents - beginning of period | 259 | 1,120 | 4,242 | - |
| Cash and cash equivalents - end of period | 954 | 259 | 1,120 | - |
Arcadia Biosciences, Inc. (RKDA)
Arcadia Biosciences, Inc. (RKDA)